COPD is a chronic lung and airways disease in which the airways are constricted, making it difficult to breathe. It is the 4th cause of death in the world the 3rd in the US. It’s caused by long-term exposure to irritating gases or particulate matter, often from cigarette smoke.
People with COPD are likely to experience episodes called exacerbations, during which the lung will experience the tightening of airway passages and inflammation triggered by the activation of the body’s immune defenses. The most common cause of death occurs after a COPD exacerbation. Roughly 10% of patients will die during the hospital stay and the 2-year mortality rate following hospitalization is about 50%.
There is a clear unmet need to develop a clinically useful home monitoring disease management tool that will enable:
- Early detection of disease exacerbations
- Monitor disease status continuously
- Follow and control patient medication adherence
- Save patients live and high costs to the healthcare system
RespirAI develops a game-changing, home-monitoring AI platform with a mission to detect early exacerbations of chronic diseases, while enabling patients, their families, and care providers to better disease management thus improving patients’ quality of life. RespirAI platform includes a chest patch that captures medical physiological data and an application that monitors the patients’ disease status.
The core technology of the system is based on an invention of researchers from the University of Nebraska at Omaha who developed a novel home monitoring wearable device, which leverages artificial intelligence (AI) capabilities to early detect COPD exacerbations before they happen.